Infections |
4 |
658 |
1.04 (0.73; 1.47) |
66% |
0.03 |
Insufficient responses to MTX |
333 Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S,
Petersson IF, et al. Conventional combination treatment versus biological treatment in
methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised,
non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–20.,2828 Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et
al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis.
2008;67(8):1096–103.,3232 Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A
multicenter, double-blind, randomized, placebo controlled trial of infliximab combined
with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol.
2006;33(1):37–44.
|
629 |
1.21 (0.75; 1.98) |
57% |
0.10 |
MTX-naïve patients |
13030 Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens
R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging
study comparing the effects of methotrexate alone, methotrexate in combination with
infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
Arthritis Rheum. 2007;56(12):3919–27.
|
29 |
0.81 (0.61; 1.06) |
– |
– |
Serious infections |
6 |
2128 |
1.19 (0.48; 2.93) |
56% |
0.08 |
Insufficient responses to MTX |
433 Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S,
Petersson IF, et al. Conventional combination treatment versus biological treatment in
methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised,
non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–20.,2828 Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et
al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis.
2008;67(8):1096–103.,3434 Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The
safety of infliximab, combined with background treatments, among patients with rheumatoid
arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
Arthritis Rheum. 2006;54(4):1075–86.,3636 Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden
JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis.
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study
Group. N Engl J Med. 2000;343(22):1594–602.
|
1428 |
0.83 (0.33; 2.06) |
31% |
0.24 |
MTX-naïve patients |
22727 Clair EWS, Van der Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis – A
randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.,3030 Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens
R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging
study comparing the effects of methotrexate alone, methotrexate in combination with
infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
Arthritis Rheum. 2007;56(12):3919–27.
|
700 |
2.80 (1.14; 6.84) |
– |
– |
Serious adverse events |
8 |
2397 |
1.02 (0.79; 1.33) |
0% |
0.57 |
Insufficient responses to MTX |
633 Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S,
Petersson IF, et al. Conventional combination treatment versus biological treatment in
methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised,
non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–20.,2828 Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et
al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis.
2008;67(8):1096–103.,2929 Zhang F-C. Infliximab versus placebo in rheumatoid arthritis patients
receiving concomitant methotrexate: a preliminary study from China. Aplar J Rheumatol.
2006;9(2):127–30.,3232 Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A
multicenter, double-blind, randomized, placebo controlled trial of infliximab combined
with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol.
2006;33(1):37–44.,3434 Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The
safety of infliximab, combined with background treatments, among patients with rheumatoid
arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
Arthritis Rheum. 2006;54(4):1075–86.,3636 Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden
JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis.
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study
Group. N Engl J Med. 2000;343(22):1594–602.
|
1697 |
0.86 (0.61; 1.21) |
0% |
0.57 |
MTX-naïve patients |
22727 Clair EWS, Van der Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis – A
randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.,3030 Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens
R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging
study comparing the effects of methotrexate alone, methotrexate in combination with
infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
Arthritis Rheum. 2007;56(12):3919–27.
|
700 |
1.32 (0.87; 1.98) |
0% |
0.63 |
Tumours |
7 |
2369 |
1.87 (0.42; 8.35) |
0% |
0.92 |
Insufficient responses to MTX |
633 Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S,
Petersson IF, et al. Conventional combination treatment versus biological treatment in
methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised,
non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–20.,2828 Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et
al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis.
2008;67(8):1096–103.,2929 Zhang F-C. Infliximab versus placebo in rheumatoid arthritis patients
receiving concomitant methotrexate: a preliminary study from China. Aplar J Rheumatol.
2006;9(2):127–30.,3232 Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A
multicenter, double-blind, randomized, placebo controlled trial of infliximab combined
with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol.
2006;33(1):37–44.,3434 Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The
safety of infliximab, combined with background treatments, among patients with rheumatoid
arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
Arthritis Rheum. 2006;54(4):1075–86.,3535 Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo
in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase
III trial. Lancet. 1999;354(9194):1932–9.
|
1698 |
1.87 (0.42; 8.35) |
0% |
0.92 |
MTX-naïve patients |
12727 Clair EWS, Van der Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis – A
randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.
|
671 |
– |
– |
– |
Tuberculose |
5 |
1928 |
4.12 (0.47; 36.07) |
0% |
0.78 |
Insufficient responses to MTX |
42828 Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et
al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis.
2008;67(8):1096–103.,2929 Zhang F-C. Infliximab versus placebo in rheumatoid arthritis patients
receiving concomitant methotrexate: a preliminary study from China. Aplar J Rheumatol.
2006;9(2):127–30.,3232 Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A
multicenter, double-blind, randomized, placebo controlled trial of infliximab combined
with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol.
2006;33(1):37–44.,3434 Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The
safety of infliximab, combined with background treatments, among patients with rheumatoid
arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
Arthritis Rheum. 2006;54(4):1075–86.
|
1265 |
2.97 (0.12; 71.81) |
– |
– |
MTX-naïve patients |
12727 Clair EWS, Van der Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis – A
randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.
|
663 |
5.48 (0.28; 105.67) |
– |
– |
Death |
6 |
2052 |
1.05 (0.20; 5.42) |
0% |
0.55 |
Insufficient responses to MTX |
433 Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S,
Petersson IF, et al. Conventional combination treatment versus biological treatment in
methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised,
non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–20.,2828 Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et
al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis.
2008;67(8):1096–103.,3232 Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A
multicenter, double-blind, randomized, placebo controlled trial of infliximab combined
with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol.
2006;33(1):37–44.,3434 Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The
safety of infliximab, combined with background treatments, among patients with rheumatoid
arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
Arthritis Rheum. 2006;54(4):1075–86.
|
1352 |
2.47 (0.26; 23.61) |
0% |
0.86 |
MTX-naïve patients |
22727 Clair EWS, Van der Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis – A
randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.,3030 Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens
R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging
study comparing the effects of methotrexate alone, methotrexate in combination with
infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
Arthritis Rheum. 2007;56(12):3919–27.
|
700 |
0.40 (0.04; 4.38) |
– |
– |
Infusion reactions |
3 |
1042 |
2.21 (1.63; 2.99) |
72% |
0.03 |
Insufficient responses to MTX |
22828 Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et
al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis.
2008;67(8):1096–103.,3232 Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A
multicenter, double-blind, randomized, placebo controlled trial of infliximab combined
with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol.
2006;33(1):37–44.
|
371 |
1.52 (1.02; 2.26) |
0% |
0.40 |
MTX-naïve patients |
12727 Clair EWS, Van der Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis – A
randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.
|
671 |
3.16 (1.98; 5.03) |
– |
– |